Friday 6 November 2026
Export RXST’s income statement to Excel — free account
RxSight, Inc.
RXST Healthcare Medical Devices
RxSight, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $134.5 million, down 3.89% from fiscal 2024.
- Revenue
- −19.0%
- EPS
- −62.1%
- Free cash flow
- +2,591.1%
Quarter to September 2026, against a year earlier
4.57
0.03
+0.66%
Follow RXST
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.68 | 1.57 | 2.00 | 3.17 | |
P/FCF ratio |
10.96 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
4.52 | (20.97) | (23.36) | (381.42) | |
P/B ratio |
0.80 | 0.76 | 0.95 | 1.54 | |
Price to Tangible BV |
0.80 | 0.76 | 0.95 | 1.54 | |
EV/Sales |
(0.25) | 0.08 | 0.44 | 1.61 | |
EV/EBITDA |
0.47 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.30) | (0.47) | (3.20) | (14.00) | |
EV/FCF |
(1.65) | (0.40) | (2.60) | (11.23) | |
Quick Ratio |
3.62 | 3.57 | 8.78 | 9.58 | |
Current Ratio |
4.20 | 4.07 | 10.20 | 10.95 | |
Net Debt/EBITDA |
13.20 | 14.38 | 11.56 | 18.52 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.38 | 0.39 | 0.41 | 0.43 | |
Operating CF/Net income |
(2.79) | 0.79 | 0.69 | 0.12 | |
Capex/Depreciation |
1.52 | 2.60 | 0.74 | 1.16 | |
Interest Coverage |
(6,172.67) | (4,590.00) | (5,943.00) | (2,834.00) | |
Research and Development Expense of Revenue |
37.47% | 27.38% | 30.66% | 27.31% | |
Selling, General and Administrative Expense of Revenue |
111.46% | 90.15% | 103.11% | 84.93% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
31.05% | 22.12% | 25.72% | 23.97% | |
Graham Net Nets |
1.12 | 1.19 | 0.95 | 0.59 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(26.10%) | (23.44%) | (18.34%) | (9.12%) | |
Free Cash Flow Yield |
9.12% | (13.58%) | (8.48%) | (4.54%) | |
Revenue per Share |
0.59 | 0.81 | 0.75 | 0.80 | |
Operating CF per Share |
1.08 | (0.23) | (0.26) | (0.03) | |
Capex per Share |
(0.03) | (0.05) | (0.02) | (0.03) | |
Free Cash Flow per Share |
1.06 | (0.28) | (0.28) | (0.06) | |
Cash per Share |
6.11 | 5.03 | 5.27 | 5.58 | |
Shareholders Equity per Share |
6.11 | 6.35 | 6.47 | 6.75 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.11 | 6.35 | 6.47 | 6.75 | |
Free Cash Flow |
44.04 | (11.49) | (11.65) | (2.25) | |
Working Capital |
239.85 | 246.95 | 251.85 | 261.21 | |
Capital Expenditures |
(1.17) | (1.96) | (0.76) | (1.14) | |
Net Current Asset Value |
229.30 | 238.04 | 242.53 | 251.33 | |
EV/EBIT |
0.50 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.06 | 0.02 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
20.57 | 53.29 | 26.70 | 26.72 | |
Average Payables |
3.40 | 4.85 | 7.12 | 4.92 | |
Average Inventory |
34.27 | 31.09 | 29.22 | 26.78 | |
Average Assets |
324.48 | 330.85 | 308.52 | 315.19 | |
Average Common Equity |
265.44 | 270.68 | 273.31 | 278.46 |
Columns are period end dates · fundamentals updated 5 Nov 2026